Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Completion of Phase 1 Study for Lead AutoimmuneInflammatory Disease Program ALPN101BALANCE Trial of ALPN101 in Acute GVHD Open for EnrollmentNEON1 Trial of ALPN202 in Advanced Malignancies Open for EnrollmentOrphan Drug Designations by the U.S. FDA for ALP...